Risk of drug interaction: Combination of antidepressants and other drugs;Risco de interação de drogas: Combinações de uso de antidepressivos e outras drogas

Revista de Saude Publica

Volumn 37, Issue 2, 2003, Pages 212-215

  Sakiara Miyasaka, Lincoln ^a   Nagib Atallah, Alvaro ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antidepressive agents; Drug interactions; Drug utilization; Prescriptions, drug; Risk assessment

Indexed keywords

AMINEPTINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; FLUOXETINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; MOCLOBEMIDE; NORTRIPTYLINE; PAROXETINE; TRANYLCYPROMINE;

ARTICLE; BRAZIL; COMPUTER PROGRAM; CONTROLLED STUDY; DEPRESSION; FEMALE; HOSPITAL ADMISSION; HOSPITAL INFORMATION SYSTEM; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MANUAL LABOR; MOOD DISORDER; OUTPATIENT DEPARTMENT; PRESCRIPTION; PSYCHIATRIC DEPARTMENT; PUBLIC HOSPITAL; REGISTRATION; RISK ASSESSMENT;

EID: 0038415800     PISSN: 00348910     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0034-89102003000200008     Document Type: Article

References (15)

1. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: depression and mania. In: Goodman and Gilman's. The pharmacological basis of the therapeutics. 9th ed. New York: McGraw-Hill; 1996.
2. Blacker CVR, Clare AW. Depressive disorder in primary care. Br J Psychiatry 1987;150:737-51.
3. Furlanetto LM. Diagnosticando depressão em pacientes internados em enfermarias de clínica médica. J Bras Psiquiatr 1996;45:363-70.
4. Goldberg D, Huxley P. Mental illness in the community. The pathway to psychiatric care. London: Tavistock; 1980.
5. Greenblatt DJ, Moltke LL, Harmatz JS, Shader IS. Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry 1998;59 Suppl 15:19-27.
6. Hales RE, Yudofsky SC, Talbot JA. Textbook of psychiatry. 2nd ed. Washington (DC): The American Psychiatric Press; 1994.
7. Jefferson JW, Greist JH. Mood disorders. In: Hales RE, Yudofsky SC, Talbot JA. Textbook of psychiatry. 2nd ed. Washington (DC): The American Psychiatric Press; 1994.
8. Kaplan HI, Sadock BJ. Synopsis of psychiatry, Ch 15 mood disorders. 8th ed. Baltimore: Williams and Wilkins; 1998. p. 524-80.
9. Lamberg L. Treating depression in medical conditions may improve quality of life. JAMA 1996;11:857-8.
10. Mari JJ, Williams P. A validity study of a psychiatric screening questionnaire (SRQ-20) in primary care in the city of São Paulo. Br J Psychiatry 1986;148:23-6.
11. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and cytochrome P450 system. Am J Psychiatry 1996;153:311-20.
12. Reichenheim ME, Harpham T. Maternal mental health in a squatter settlement in Rio de Janeiro. Br J Psychiatry 1991;159:683-90.
13. Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proced 1997;72:835-47.
14. Todi SK, Hartmann RA. Ch 32 Pharmacologic Principles, In: Civetta JM, Taylor RW, Kirby RR. Critical care. 3rd ed. Philadelphia, NY: Lippincott-Raven Publishers; 1997. p. 485-8.
15. Weissman MM, Leaf PJ, Tischler GL, Blazer DG, Karno M, Livingston M, Florio LP. Affective disorders in five United States communities. Psychol Med 1988;18:141-53.